Pharmacodynamics of Radiolabelled Anticancer Drugs for Positron Emission Tomography

Author(s): O. Clyde Hutchinson, David R. Collingridge, Henryk Barthel, Pat. M. Price, Eric O. Aboagye

Journal Name: Current Pharmaceutical Design

Volume 9 , Issue 11 , 2003

Become EABM
Become Reviewer


Positron Emission Tomography (PET) offers an exciting opportunity to monitor key pathways involved in malignant transformation due to the ability to radiolabel and image the behaviour of biological probes. In this review, we will describe how PET can use various radiolabelled compounds to monitor various targets including ligand-receptor interactions using 16α-[18F]fluoro-17β-oestradiol (FES) pathways involved in metabolism with [18F]fluorodeoxy-glucose ([18F]FDG), 11C-methyl-choline for signal transduction, cell cycle and proliferation with 2-[11C]thymidine, cell death using [124I]annexin V, [11C]colchicine for drug resistance and angiogenesis using [124I]anti-VEGF.

Keywords: Pharmacodynamics, Radiolabelled, Anticancer Drugs, 11C-methyl-choline, ligand-receptor, Positron Emission Tomography (PET)

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2003
Page: [931 - 944]
Pages: 14
DOI: 10.2174/1381612033455251
Price: $65

Article Metrics

PDF: 5